GlobeNewswire·Jul 14, 2026, 8:00 AM ET

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Inhibikase Therapeutics, Inc. sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market facility for $50 million in gross proceeds.
The company expects the raised capital, combined with existing cash reserves, to fund operations through the top-line data readout of Part B in the Phase 3 IMPROVE-PAH study, assuming full exercise of outstanding Series A and B Warrants.
The sale was executed under a shelf registration statement on Form S-3 declared effective by the SEC on June 27, 2025, along with an ATM prospectus supplement filed on December 19, 2025.
Inhibikase is developing IKT-001, a prodrug of imatinib mesylate, as a treatment for Pulmonary Arterial Hypertension (PAH) in a global Phase 3 study enrolling patients at approximately 180 sites.
The press release includes forward-looking statements regarding cash runway and study execution that are subject to risks and uncertainties that could cause actual results to differ materially from expectations.